Business Context and Reporting Period
Company: Ascentage Pharma Group International
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of May 2026
Date of Filing: May 28, 2026
Principal Executive Offices: Suzhou, Jiangsu, China
Key Event
The filing reports the issuance of an announcement titled "Purchase of Shares by the Trustee for the Purpose of the 2022 RSU Scheme."
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document serves solely to disclose a corporate action regarding share purchases and does not contain financial statements.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document focuses exclusively on the execution of the 2022 Restricted Stock Unit (RSU) Scheme.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies beyond the specific disclosure of the share purchase activity.
Investor Verification Checklist
- Verify the specific number of shares purchased by the Trustee under the 2022 RSU Scheme (details likely in Exhibit 99.1).
- Confirm the total cost and average price per share for the transaction.
- Review the remaining balance of the 2022 RSU Scheme following this purchase.